The tweet was deleted by the author.
But we saved everything 🙂.
Humacyte is set to present new scientific research on acellular tissue engineered vessels at the Vascular Access Society of the Americas (VASA) meeting.
The study examines the performance of these vessels after repeated cannulation, which is critical for patients requiring dialysis access. The presentation aims to offer insights into the durability and effectiveness of ATET in clinical settings. Further information is available through the official event channels.
Humacyte recently had its marketing application for the Symvess acellular vessel accepted by the Israel Ministry of Health, starting a 180-day review process. The company has also reported that 20 percent of vascular injury patients arrive at hospitals late, raising the risk of amputation, according to company estimates. These developments provide further context for Humacyte’s ongoing research presentations.